Theralase Technologies Inc. V.TLT

Virus potential alone IMHO is worth current sp. End of 2qua

[Oden6570]

Bird flu will be the next pandemic unless health officials take 6 critical steps, experts say | Fortune Well

Kevin Coombs, Ph.D., Professor, Medical Microbiology, University of Manitoba stated, “My team and I were excited by the results we have obtained as we have worked with several anti-viral compounds over the years and have found that RuvidarTM is far more potent than any of the others we have worked with, in fact RuvidarTM is effective at concentrations approximately 100-fold lower than those we have previously tested. I believe RuvidarTM has the potential to be effective as a broad-spectrum viral vaccine able to mitigate the biothreat of various emerging infectious disease pathogens. In our research, we found that nanomolar and micromolar concentrations of RuvidarTM were all that was required in order to inactivate 90 to 99.9% of all seven viruses that we tested, including H1N1 influenza virus, coronavirus, Zika virus, poxvirus and herpes virus. In fact, RuvidarTM at 3 mM completely killed the herpes virus.”

Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase® stated, “Theralase® is very excited about the acceptance of our publication to Heliyon. This publication substantiates the years of work that the team has undertaken to demonstrate that RuvidarTM is an effective technology to inactivate numerous viruses both with and without the presence of light and can be used as a strong antiviral platform in the production of vaccines in the near future, subject to completion of animal and toxicology testing. As a result, the Theralase® lab in Toronto will focus on using RuvidarTM to research and develop a topical therapeutic to mitigate the impact of herpes virus lesions. I look forward to supporting the implementation of this technology at the commercial level.”

According to the World Health Organization (“WHO”) in 2023, an estimated 3.7 billion people under the age of 50 (67%) globally have Herpes Simplex Virus type 1 (“HSV-1”) infection, the main cause of oral herpes, while an estimated 491 million people aged 15 to 49 (13%) worldwide have Herpes Simplex Virus type 2 (“HSV-2”) infection, the main cause of genital herpes.

Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer, Theralase® stated, “The small molecule RuvidarTM has been preclinically proven to kill bacteria and various cancer cells and clinically proven to kill bladder cancer cells. It is currently under preclinical evaluation in the destruction of brain cancer, lung cancer and various blood-based cancers, such as: leukemia, lymphoma and multiple myeloma. Based on the latest research detailing RuvidarTM’s success in the destruction of various viruses, the Company has gained consensus from the National Microbiology Laboratory to direct its research away from the Covid-19 virus vaccine to develop this technology for an avian influenza vaccine.”